Indian Pharma giant Dr. Reddy's Laboratories announced (In a press release here)
that it has launched the following five products in the US market during the month of January:
1. Levetiracetam tablets (250mg, 500mg, 750mg & 1000mg), the generic version of UCB Keppra® Tablets – with IMS annual sales of $1.1 billion.
2. Omeprazole capsules (40mg), the generic version of AstraZeneca's Prilosec® DR Capsules 40mg – with IMS annual sales of $168 mn.
3. Lamotragine CD chewable tablets (5mg & 25mg), the generic version of GlaxoSmithKline's Lamictal® CD Tablets – with IMS annual sales of $87 mn.
4. Divalproex capsules & delayed release pellets (125mg), the generic version of Abbott's
that it has launched the following five products in the US market during the month of January:
1. Levetiracetam tablets (250mg, 500mg, 750mg & 1000mg), the generic version of UCB Keppra® Tablets – with IMS annual sales of $1.1 billion.
2. Omeprazole capsules (40mg), the generic version of AstraZeneca's Prilosec® DR Capsules 40mg – with IMS annual sales of $168 mn.
3. Lamotragine CD chewable tablets (5mg & 25mg), the generic version of GlaxoSmithKline's Lamictal® CD Tablets – with IMS annual sales of $87 mn.
4. Divalproex capsules & delayed release pellets (125mg), the generic version of Abbott's
5. Depakote® Delayed Release Capsules 125mg – with IMS annual sales of $126 mn. Lamotrigine tablets (25mg, 100mg, 150mg & 200mg), the generic version of GlaxoSmithKline's Lamictal® Tablets – with IMS annual sales of $2.3 billion.
No comments:
Post a Comment